Date Title Description PDF
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download

Pages

Date Title Description PDF
07 Nov 2024 On P&L A correction to the English version of a document is reported. Download
03 Oct 2024 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the third quarter of 2024 Download
12 Sep 2024 Other relevant information The Company announces the registration in the Commercial Registry of the public deed of reduction of its share capital and the new share capital figure. Download
01 Aug 2024 Other relevant information The Company has agreed to execute the share capital reduction approved by the 2024 Ordinary General Meeting to amortize treasury shares, among which those acquired in the framework of the own shares repurchase program. Download
31 Jul 2024 Liquidity and counterparty agreements Modification of securities and cash balances associated with the Liquidity Contract signed between the Company and Bestinver, S.V., S.A. Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages